Wegovy has raised concerns for investors in the food and beverage industry. Anheuser-Busch InBev (BUD) CEO Michel Doukeris ...

A recent study conducted in Sweden found that GLP-1 agonists such as Ozempic and Wegovy may help reduce alcohol consumption and related harms in individuals diagnosed with alcohol use disorder. Here ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

The US overweight and obese population will rise significantly in the next quarter century if current trends continue, and ...

With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years ...

For the three months ending September 30, 2024, the fund's Retail Class shares gained 6.36%, trailing the 7.29% advance of the benchmark MSCI EAFE Index. Click to read.

Fidelity International Capital Appreciation Fund is a diversified international equity strategy that seeks capital growth by ...

PhRMA's “Middleman” and “Your Insurance” characters snatch savings away from a bewildered patient.

As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide ...

(Reuters) -Chinese e-commerce group JD.com missed market estimates for quarterly revenue on Thursday, as a persistent ...

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

Ozempic and Wegovy are “forever drugs”—once a person stops taking the medications, they typically regain the weight unless ...